Common Shares Outstanding: The number of class A shares currently held by investors.
Provectus Biopharmaceuticals, Inc. (PVCT) had Common Shares Outstanding of 420.28M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-1.17M |
|
-- |
|
-- |
|
$1.12M |
|
$-1.12M |
|
$-0.05M |
|
$-1.17M |
|
$-1.17M |
|
$-1.17M |
|
$-1.17M |
|
$-1.17M |
|
$-1.17M |
|
$-1.12M |
|
$-1.12M |
|
420.28M |
|
420.28M |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$0.57M |
|
$0.00M |
|
$0.13M |
|
$0.70M |
|
$6.90M |
|
$0.02M |
|
$0.10M |
|
$7.00M |
|
$-6.32M |
|
$-6.30M |
|
$-6.30M |
|
|
Common Shares Outstanding |
420.28M |
| Cash Flow Statement Financials | |
$-3.33M |
|
-- |
|
$3.09M |
|
$0.49M |
|
$0.25M |
|
$-0.24M |
|
$1.24M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.08 |
|
-- |
|
-- |
|
-0.00 |
|
-0.45 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.33M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
18.48% |
|
18.53% |
|
-167.43% |
|
18.60% |
|
$-0.01 |
|
$-0.01 |
|
$-0.01 |
|